Filter
Exclude
Time range
-
Near
Katie Gorick retweeted
The year's highlight for Dr. Price? Launching the world's 1st center for #FUS #cancerimmunotherapy? Nope - it's his lab! "From my office I overhear them raising each other up through new challenges on a daily basis. It's inspiring.” @PriceLabUVaBME MORE: bit.ly/fus-win
0
5
0
24
Frontiers in Cancer Immunotherapy is available to stream through August! Register now to hear from Keynote Speakers! #cancerimmunotherapy #cancerresearch #immunotherapy bit.nyas.org/3PqiYNA
0
0
1
1
"Immuno-oncology involves expanding and training immune cells to recognize and kill cancer cells." @OSUWexMed @OSUCCC_James researcher and #PIIO Director @Zihai Li answers more questions about #IO and #CancerImmunotherapy on this health.osu.edu Q&A
An @OhioState expert explains how immunotherapy and other immuno-oncology treatments harness patients' own bodies to target and kill cancer cells. health.osu.edu/health/cancer…
0
0
0
7
Certainly, holds true for many cancers sensitive to #cancerimmunotherapy.
Interesting, as median PFS differences was only 1.5 months. Suggests PFS is not a terrific surrogate for OS in ER+ advanced breast cancer which would have major implications for many drugs in development.
0
0
0
0
All due respect to rad onc colleagues, but I once said would be great to get rid of RT (and high dose CDDP) for advanced SCCHN using early #cancerimmunotherapy and med onc collegue said "you're dreaming, getting rid of RT aint never going to happen" 😀
0
0
0
0
Yet again more data indirectly suggesting the negative effects of high dose alkylators like cisplatin causing immune system impairment and/or selecting resistant #cancer cells to later line #cancerimmunotherapy in advanced SCCHN.
Neoadjuvant IO, whether alone or in combination, can lead to pCR. In this study, if 1/3 patients has pCR, do we need adjuvant RT? Why not substitute adjuvant IO? Worth studying. aacrjournals.org/clincancerr…
0
0
0
0
Long-standing problem of Ag loss variants continues to remain problematic and fuels work into immunosurveillance, immunoediting, clonality, targeting multiple neoantigens & underappreciated bystander contributions to successful #cancerimmunotherapy
0
0
0
0
More excellent work on Ag presenting cells, T1 cytokine loops & underappreciated need for CD4 activation/regulation help in effector mechanisms of #cancerimmunotherapy in this model #immunotherapy #immunology
SPOTLIGHT: Neoantigen Presentation and IFNγ Signaling on the Same Tumor-associated Macrophage are Necessary for CD4 T [...] @AperezdiezDiez. Originally published in @CRC_AACR. To read our summary click ow.ly/YI8850KgytZ and scroll all the way down.
0
0
0
3
Ongoing understanding of TCR avidity & development against HLA restricted neoantigens is critical for determining immunosurveillance, biomarker development & #immunoengineering #cancerimmunotherapy #immunotherapy #immunology
New research explores the connection between high-avidity T cells (TCR) in the peripheral blood and improved anti-tumor responses. @Jarosch_S @kischober @TU_Muenchen 📝: fcld.ly/yorcnfh
0
0
0
1
Find out how scientists at the @NIH, led by Dr. John T. Schiller, have developed a new immunotherapy strategy to awaken immune responses within the tumor microenvironment and promote antigen spreading. #CancerImmunotherapy #Immunology #Research #Health #Science
0
0
0
0
Ag presentation loss has been known for decades to be associated with poor outcomes to various #cancerimmunotherapy approaches. Many #cancer #molecularprofiling companies don't include HLA expression. Brought it up at #ASCO22 & young panelist called it "hubris."😀 Kudos @vib_ccb
About 50-60% of advanced melanoma patients do not respond to immunotherapy. Why and what can we do about it? In this preprint we describe a prospective longitudinal clinical study we designed/conducted to address this (1/9). biorxiv.org/cgi/content/shor…
Show this thread
0
0
0
0
Dr. @ChiappinelliLab talks about pursuing future research in this exciting area and offers career advice for other early career researchers. aacrjournals.org/cancerres/a… @GWSMHS @GWCancer #OvarianCancer #CancerImmunotherapy
Watch our interview with Dr. @ChiappinelliLab, 2022 Cancer Research Early Career Award recipient, discussing her article on epigenetic drugs in #OvarianCancer and the role of p53 in altering repetitive DNA transcription. bit.ly/3Pk0SME @GWSMHS @GWCancer
0
0
0
0
Sinai Immunology retweeted
Happy Monday! Our lab is hiring research associates, students, postdoctoral fellows. We study #CancerImmunotherapy and are part of a vibrant scientific community at @SinaiImmunol @TischCancer, located <5 min from Central Park in NYC 🗽! Lab website link: labs.icahn.mssm.edu/bhardwaj…
2
9
1
23
Show this thread